Prognostic value of transforming growth factor-beta in patients with colorectal cancer who undergo surgery: a meta-analysis

BMC Cancer

Research Article

Lei Lian¹  Yi-sheng Su²  Tian-wen Liu²  Xu-jie Xi²  Yue Hu³  Xin-lin Chen³  Feng-bin Liu⁴  Yi Wen⁵  Shui-lian Zhu⁵  Zhuo-qun Chen⁵ 

[1] Department of Colorectal Surgery, Sun Yat-sen University, Guangzhou, China;Guangdong Province Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China;School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, China;The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China;The First Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China;

关键词: Colorectal cancer;    Transforming growth factor-beta;    TGF-β;    Prognosis;    Meta-analysis;   

DOI  :  10.1186/s12885-017-3215-7

 received in 2016-08-02, accepted in 2017-03-22,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundTransforming growth factor-beta (TGF-β) is associated with a higher incidence of distant metastasis and decreased survival. Whether TGF-β can be used as a prognostic indicator of colorectal cancer (CRC) remains controversial.MethodsThe Medline, EMBASE and Cochrane databases were searched from their inception to March 2016. The studies that focused on TGF-β as a prognostic factor in patients with CRC were included in this analysis. Overall survival (OS) and disease-free survival (DFS) were analysed separately. A meta-analysis was performed, and hazard ratios (HR) with 95% confidence intervals (CI) were calculated.ResultsTwelve studies were included in the analysis, of which 8 were used for OS and 7 for DFS. In all, 1622 patients with CRC undergoing surgery were included. Combined HRs suggested that high expression of TGF-β had a favourable impact on OS (HR = 1.68, 95% CI: 1.10–2.59) and DFS (HR = 1.11, 95% CI: 1.03–1.19) in CRC patients. For OS, the combined HRs of Asian studies and Western studies were 1.50 (95% CI: 0.61–3.68) and 1.80 (95% CI: 1.33–2.45), respectively. For DFS, the combined HRs of Asian studies and Western studies were 1.42 (95% CI: 0.61–3.31) and 1.11 (95% CI: 1.03–1.20), respectively.ConclusionsThis meta-analysis demonstrates that TGF-β can be used as a prognostic biomarker for CRC patients undergoing surgery, especially for CRC patients from Western countries.

【 授权许可】

CC BY   
© The Author(s). 2017